Rep. Norm Thurston — Voting Record

Utah House District 62 · complete roll-call record from le.utah.gov
← All votes

Bill

Right to Try Amendments
Number
S.B. 222 (2026GS)
Sponsor
Sen. Wilson, Chris H.
Final action
Governor Signed 3/18/2026
Outcome
Became law — signed by Gov. Spencer J. Cox

Summary

This bill amends provisions related to when a patient may obtain and use investigational drugs and devices to treat an illness.

What it does

  • This bill:
  • allows a patient to obtain an investigational drug or device in additional circumstances;
  • amends the definition regarding the forms a medicine may take; and
  • creates a reporting requirement for manufacturers.

Every vote on this bill

2026-02-03Senate Comm - Favorable Recommendation
Senate Health and Human Services Committee
3-1-3not eligible / no record
2026-02-27House Comm - Favorable Recommendation
House Health and Human Services Committee
10-0-4not eligible / no record
2026-03-05House/ passed 3rd reading
House Speaker
67-0-8YEA
2026-02-20Senate/ substituted
Senate 2nd Reading Calendar
0-0-29not eligible / no record
2026-02-20Senate/ passed 2nd reading
Senate 3rd Reading Calendar
23-0-6not eligible / no record
2026-02-23Senate/ substituted
Senate 3rd Reading Calendar
0-0-29not eligible / no record
2026-02-23Senate/ circled
Senate 3rd Reading Calendar
0-0-29not eligible / no record
2026-02-23Senate/ uncircled
Senate 3rd Reading Calendar
0-0-29not eligible / no record
2026-02-23Senate/ passed 3rd reading
Clerk of the House
24-0-5not eligible / no record

Bill text

enrolled version · official source
8
58-85-102
58-85-107
0
Right to Try Amendments
2026 GENERAL SESSION
STATE OF UTAH
Chief Sponsor: Chris H. Wilson
House Sponsor: Tyler Clancy
LONG TITLE
General Description:
This bill amends provisions related to when a patient may obtain and use investigational 
drugs and devices to treat an illness.
Highlighted Provisions:
This bill:
allows a patient to obtain an investigational drug or device in additional circumstances;
amends the definition regarding the forms a medicine may take; and
creates a reporting requirement for manufacturers.
Money Appropriated in this Bill:
None
Other Special Clauses:
None
Utah Code Sections Affected:
AMENDS:
58-85-102
, as last amended by Laws of Utah 2025, Chapter 114
ENACTS:
58-85-107
, Utah Code Annotated 1953
Be it enacted by the Legislature of the state of Utah:
Section 1. Section 
58-85-102
 is amended to read:
58-85-102
. Definitions.
As used in this chapter:
(1)
"Eligible illness" means a condition of a patient that:
(a)
as determined by a physician, presents a substantial and severely debilitating or 
life-threatening risk to the patient; and
(b)
presents the patient, after the patient has explored conventional therapy options, with 
no treatment option that is satisfactory or comparable to treatment with an 
investigational drug or investigational device.
(2)
"Eligible patient" means an individual who has been diagnosed with a terminal illness
 or 
eligible illness
 by a physician.
(2)
(3)
"Insurer" means the same as that term is defined in Section 
31A-1-301
.
(3)
(4)
"Investigational device" means a device that:
(a)
meets the definition of "investigational device" in 21 C.F.R. Sec. 812.3;
 and
(b)
has successfully completed the United States Food and Drug Administration Phase 1 
testing for an investigational device described in 21 C.F.R. Part 812
.
; and
(c)
if used to treat an eligible illness, is currently undergoing an investigation, as defined 
in 21 C.F.R. Sec. 812.3, that complies with all applicable requirements for the 
investigation in accordance with 21 C.F.R. Part 812.
(4)
(5)
"Investigational drug" means a drug that:
(a)
meets the definition of "investigational new drug" in 21 C.F.R. Sec. 312.3;
 and
(b)
has successfully completed the United States Food and Drug Administration Phase 1 
testing for an investigational new drug described in 21 C.F.R. Part 312
.
; and
(c)
if used to treat an eligible illness, is currently undergoing a clinical investigation, as 
defined in 21 C.F.R. Sec. 312.3, that complies with all applicable requirements for 
the clinical investigation in accordance with 21 C.F.R. Part 312.
(5)
(6)
"Medicinal dosage form" means:
(a)
a tablet;
(b)
a capsule;
(c)
a concentrated oil;
(d)
a liquid 
suspension
formulation
;
(e)
a transdermal preparation; or
(f)
a sublingual preparation.
(6)
(7)
"Physician" means an individual who is licensed under:
(a)
Title 58, Chapter 67, Utah Medical Practice Act
; or
(b)
Title 58, Chapter 68, Utah Osteopathic Medical Practice Act
.
(7)
(8)
"Terminal illness" means a condition of a patient that:
(a)
(i)
as determined by a physician:
(i)
(A)
is likely to pose a greater risk to the patient than the risk posed to the 
patient by treatment with an investigational drug or investigational device; and
(ii)
(B)
will inevitably lead to the patient's death; 
and
or
(ii)
as determined by a physician who is a board certified oncologist, is cancer; and
(b)
presents the patient, after the patient has explored conventional therapy options, with 
no treatment option that is satisfactory or comparable to treatment with an 
investigational drug or device.
Section 2. Section 
58-85-107
 is enacted to read:
58-85-107
. Repo
rt.
(1)
If a manufacturer of an investigational drug or investigational device provides an 
investigational drug or investigational device to a patient located in the state to treat an 
eligible illness, the manufacturer shall report 
the
inform
ation described in Subsection 
(2)
to the Health and Human Services Interim Committee before the November 1 that 
follows the day the drug or device was provided to the patient.
(2)
The report shall include the following information:
(a)
the number of patients that received an investigational drug or investigational device 
to treat an eligible illness;
(b)
each eligible illness being treated;
(c)
adverse outcomes likely attributable to the investigational drug or investigational 
device; and
(d)
any other information the manufacturer dete
rmine
s
relevant.
(3)
Subsection 
(1)
 does not apply if the patient receiving the device or drug was part of 
an 
investigation
 conducted under 21 C.F.R. Part 812 or a clinical investigation conducted 
under 21 C.F.R. Part 312.
Section 3. 
Effective Date.
This bill takes effect on 
May 6, 2026
.
3-11-26 4:36 PM